Similarly, targeting molecules on tumor-specific T cells that are involved in the regulation of T cell survival and effector functions (e.g., IL-7, IL-15, activating antibodies to CD137, blocking CTLA-4 [132-135]) might translate into improved clinical outcomes. The gene discussed is IL7; the disease is neoplasm.